These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19517748)

  • 1. [Ivabradine, an I(f) current inhibitor--new treatment options in coronary heart disease].
    Mach F
    Rev Med Suisse; 2009 May; 5(205):1168-70, 1172-3. PubMed ID: 19517748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the management of heart failure: the role of ivabradine.
    Müller-Werdan U; Stöckl G; Werdan K
    Vasc Health Risk Manag; 2016; 12():453-470. PubMed ID: 27895488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease.
    Vilaine JP
    Pharmacol Res; 2006 May; 53(5):424-34. PubMed ID: 16638639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):807-16. PubMed ID: 18757088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina.
    Sulfi S; Timmis AD
    Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel If current inhibitor ivabradine: safety considerations.
    Savelieva I; Camm AJ
    Adv Cardiol; 2006; 43():79-96. PubMed ID: 16936474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
    Mulder P; Barbier S; Chagraoui A; Richard V; Henry JP; Lallemand F; Renet S; Lerebours G; Mahlberg-Gaudin F; Thuillez C
    Circulation; 2004 Apr; 109(13):1674-9. PubMed ID: 14981003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction.
    Camici PG; Gloekler S; Levy BI; Skalidis E; Tagliamonte E; Vardas P; Heusch G
    Int J Cardiol; 2016 Jul; 215():1-6. PubMed ID: 27104917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Coronary heart disease. Rapid heart rate has an unfavorable prognosis].
    Einecke D
    MMW Fortschr Med; 2008 Sep; 150(38):12-4. PubMed ID: 18983046
    [No Abstract]   [Full Text] [Related]  

  • 11. Update on ivabradine for heart failure.
    Borer JS; Tavazzi L
    Trends Cardiovasc Med; 2016 Jul; 26(5):444-9. PubMed ID: 26934996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation.
    Verrier RL; Bonatti R; Silva AF; Batatinha JA; Nearing BD; Liu G; Rajamani S; Zeng D; Belardinelli L
    Heart Rhythm; 2014 Dec; 11(12):2288-96. PubMed ID: 25111327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ivabradine in coronary heart disease: experimental and clinical pharmacology].
    Pathak A; Berdeaux A; Mulder P; Thuillez C
    Therapie; 2010; 65(5):483-9. PubMed ID: 21144484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.
    Nuding S; Ebelt H; Hoke RS; Krummenerl A; Wienke A; Müller-Werdan U; Werdan K
    Clin Res Cardiol; 2011 Oct; 100(10):915-23. PubMed ID: 21638157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart rate reduction via selective 'funny' channel blockers.
    Bucchi A; Barbuti A; Baruscotti M; DiFrancesco D
    Curr Opin Pharmacol; 2007 Apr; 7(2):208-13. PubMed ID: 17267284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):875-85. PubMed ID: 20801500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivabradine: Heart Failure and Beyond.
    Chaudhary R; Garg J; Krishnamoorthy P; Shah N; Lanier G; Martinez MW; Freudenberger R
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):335-43. PubMed ID: 26721645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivabradine: from molecular basis to clinical effectiveness.
    Riccioni G
    Adv Ther; 2010 Mar; 27(3):160-7. PubMed ID: 20419486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivabradine: cardiovascular effects.
    Rognoni A; Bertolazzi M; Macciò S; Rognoni G
    Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):61-6. PubMed ID: 19149708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.